Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal
Bristol-Myers Squibb Company (NYSE:BMY) is a global pharmaceutical company.
Bristol Myers Squibb Co (BMY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 14,843,475 | $687,104,458 | +11% | 2.23% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 11,311,281 | $523,599,197 | +429% | 0.37% |
| 3. | GLG Partners Noam Gottesman | 7,465,845 | $345,593,965 | +281% | 0.66% |
| 4. | AQR Capital Management Cliff Asness | 6,067,940 | $280,672,583 | +2% | 0.23% |
| 5. | 3,529,500 | $163,380,555 | -26% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.33 | 56,000 | $2,650,480.00 | 167,379 | 2025-09-02 | Filing | |
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing | |
| $55.62 | 700 | $38,930.50 | 11,760 | 2024-11-04 | Filing | |
| $61.25 | 17,986 | $1,101,642.50 | 27,868 | 2023-08-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,539,425 | $69,428,087 | 0.97% | |
| 2. | 900,952 | $40,632,958 | 0.04% | |
| 3. | 639,973 | $28,862,783 | 0.25% | |
| 4. | 585,716 | $26,415,792 | 0.45% | |
| 5. | 516,959 | $23,314,851 | 0.16% |
News See All
11 Low PE High Dividend Stocks to Buy According to Analysts
A low price-to-earnings (P/E) ratio often indicates that a stock may be undervalued compared to its earnings, which makes it appealing to investors who ...
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend
Bristol-Myers Squibb Company (NYSE:BMY), headquartered in New Jersey, is a global pharmaceutical leader developing prescription drugs across areas such as oncology, hematology...
12 Best Dividend Stocks With Yields Above 4%
Investors often keep a close eye on the stock market, tracking price movements and hoping for gains.
Bristol Myers Squibb's Alzheimer's Drug, BMS-986446, Granted FDA Fast Track Status
Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 5 years.
13 Cheap Stocks to Buy For the Next 5 Years
On October 7, Ed Yardeni, Yardeni Research, joined 'Closing Bell' on CNBC to discuss what investors should focus on with stocks and suggested that valuations are high, but earnings have been remarkably...
Investing Smart: Bristol-Myers Squibb (BMY) Among the Best Affordable Dividend Stocks
Bristol-Myers Squibb Company (NYSE:BMY) is an American pharmaceutical giant that operates in multiple countries and is based in New Jersey.
Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery
Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years.
11 Best Affordable Dividend Stocks to Buy Now
With the Federal Reserve moving toward rate cuts, dividend-paying stocks could attract renewed interest from investors. Still, not all approaches deliver the same results.
10 Most Undervalued Stocks to Buy and Hold for 5 Years
On September 24, Richard Fisher, former Dallas Fed President & Jefferies senior advisor, joined 'Closing Bell' on CNBC to discuss how valuations are very strong and concentrated.